(AMUN) - Overview
Stock: ETFs, Mutual Funds, Pension Mandates, Advisory Services, Treasury
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 6.11% |
| Yield on Cost 5y | 8.93% |
| Yield CAGR 5y | 10.03% |
| Payout Consistency | 81.4% |
| Payout Ratio | 52.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 24.2% |
| Relative Tail Risk | -4.57% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.68 |
| Alpha | 13.50 |
| Character TTM | |
|---|---|
| Beta | 0.220 |
| Beta Downside | 0.261 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.65% |
| CAGR/Max DD | 0.66 |
Description: AMUN January 03, 2026
Amundi S.A. is a publicly listed French investment manager that operates across retail, institutional, and corporate client segments, offering a broad suite of mutual funds, ETFs, and advisory solutions.
In France, the firm leverages quasi-exclusive distribution agreements with the retail banking networks of Crédit Agricole and Société Générale, while internationally it expands through partner networks, joint ventures, and third-party distributors across Europe and Asia.
Amundi’s typical equity investments range from $1.31 million to $53.89 million in companies with sales between $13.09 million and $392.78 million, reflecting a focus on mid-cap opportunities that can benefit from active ownership and ESG integration.
Beyond fund management, the company provides pension, insurer, and sovereign wealth fund advisory services, as well as treasury and employee-savings solutions for corporates, supported by global relationship managers in roughly 30 countries.
Founded in 1982 and headquartered in Paris, Amundi was formerly known as Amundi Group and now functions as a subsidiary of Crédit Agricole S.A., the largest banking group in France.
Key metrics (2023): assets under management of €2.0 trillion (+7% YoY), net profit of €1.2 billion, and a 0.45% expense ratio on its flagship active equity funds, highlighting both scale and fee-compression pressures in the European asset-management sector.
Given the firm’s strong position in a market where low-interest-rate environments and rising ESG demand are reshaping client preferences, further analysis on ValueRay could help quantify its relative valuation and growth prospects.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 2.54b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.99 > 1.0 |
| NWC/Revenue: 359.0% < 20% (prev 6.88%; Δ 352.1% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.90b > Net Income 2.54b |
| Net Debt (20.32b) to EBITDA (2.36b): 8.63 < 3 |
| Current Ratio: 4.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (198.3m) vs 12m ago -3.11% < -2% |
| Gross Margin: 57.21% > 18% (prev 0.53%; Δ 5669 % > 0.5%) |
| Asset Turnover: 15.43% > 50% (prev 20.95%; Δ -5.52% > 0%) |
| Interest Coverage Ratio: 12.04 > 6 (EBITDA TTM 2.36b / Interest Expense TTM 133.7m) |
Altman Z'' 3.96
| A: 0.55 (Total Current Assets 28.07b - Total Current Liabilities 6.61b) / Total Assets 39.17b |
| B: 0.03 (Retained Earnings 997.7m / Total Assets 39.17b) |
| C: 0.04 (EBIT TTM 1.61b / Avg Total Assets 38.73b) |
| D: 0.0 (Book Value of Equity 0.0 / Total Liabilities 27.13b) |
| Altman-Z'' Score: 3.96 = AA |
What is the price of AMUN shares?
Over the past week, the price has changed by +1.03%, over one month by +9.07%, over three months by +16.90% and over the past year by +20.31%.
Is AMUN a buy, sell or hold?
What are the forecasts/targets for the AMUN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 80 | 2.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 89.9 | 15% |
AMUN Fundamental Data Overview February 08, 2026
P/E Trailing = 9.6007
P/E Forward = 10.7759
P/S = 4.6831
P/B = 1.3343
P/EG = 5.9885
Revenue TTM = 5.98b EUR
EBIT TTM = 1.61b EUR
EBITDA TTM = 2.36b EUR
Long Term Debt = 313.2m EUR (from longTermDebt, two quarters ago)
Short Term Debt = 28.6m EUR (from shortTermDebt, two quarters ago)
Debt = 20.32b EUR (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 20.32b EUR (using Total Debt 20.32b, CCE unavailable)
Enterprise Value = 36.33b EUR (16.00b + Debt 20.32b - (null CCE))
Interest Coverage Ratio = 12.04 (Ebit TTM 1.61b / Interest Expense TTM 133.7m)
EV/FCF = 19.95x (Enterprise Value 36.33b / FCF TTM 1.82b)
FCF Yield = 5.01% (FCF TTM 1.82b / Enterprise Value 36.33b)
FCF Margin = 30.46% (FCF TTM 1.82b / Revenue TTM 5.98b)
Net Margin = 42.41% (Net Income TTM 2.54b / Revenue TTM 5.98b)
Gross Margin = 57.21% ((Revenue TTM 5.98b - Cost of Revenue TTM 2.56b) / Revenue TTM)
Gross Margin QoQ = none% (prev 52.84%)
Tobins Q-Ratio = 0.93 (Enterprise Value 36.33b / Total Assets 39.17b)
Interest Expense / Debt = 0.39% (Interest Expense 79.7m / Debt 20.32b)
Taxrate = 28.81% (362.4m / 1.26b)
NOPAT = 1.15b (EBIT 1.61b * (1 - 28.81%))
Current Ratio = 4.25 (Total Current Assets 28.07b / Total Current Liabilities 6.61b)
Debt / Equity = 1.69 (Debt 20.32b / totalStockholderEquity, two quarters ago 11.99b)
Debt / EBITDA = 8.63 (Net Debt 20.32b / EBITDA 2.36b)
Debt / FCF = 11.16 (Net Debt 20.32b / FCF TTM 1.82b)
Total Stockholder Equity = 11.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.54% (Net Income 2.54b / Total Assets 39.17b)
RoE = 21.40% (Net Income TTM 2.54b / Total Stockholder Equity 11.84b)
RoCE = 13.24% (EBIT 1.61b / Capital Employed (Equity 11.84b + L.T.Debt 313.2m))
RoIC = 8.70% (NOPAT 1.15b / Invested Capital 13.17b)
WACC = 3.12% (E(16.00b)/V(36.33b) * Re(6.72%) + D(20.32b)/V(36.33b) * Rd(0.39%) * (1-Tc(0.29)))
Discount Rate = 6.72% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -1.51%
[DCF Debug] Terminal Value 83.71% ; FCFF base≈1.65b ; Y1≈1.32b ; Y5≈884.2m
Fair Price DCF = 33.59 (EV 27.20b - Net Debt 20.32b = Equity 6.88b / Shares 204.8m; r=5.90% [WACC]; 5y FCF grow -24.33% → 2.90% )
EPS Correlation: 69.59 | EPS CAGR: 4.20% | SUE: 1.19 | # QB: 2
Revenue Correlation: 11.23 | Revenue CAGR: -15.03% | SUE: -0.01 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.61 | Chg30d=-0.141 | Revisions Net=+1 | Analysts=2
EPS current Year (2026-12-31): EPS=7.22 | Chg30d=+0.150 | Revisions Net=+9 | Growth EPS=+9.7% | Growth Revenue=-0.1%
EPS next Year (2027-12-31): EPS=7.54 | Chg30d=+0.173 | Revisions Net=+6 | Growth EPS=+4.4% | Growth Revenue=+2.9%